Citations

Clear

2510 citation(s) found for "Yang, Xi".

Leukotrienes C4 and D4 Increase the Ciliary Beat Frequency in Human Upper Airway Mucosa in Vitro
Cyrus, Carlos B., Yang, Bin , McCaffrey, Thomas V.

Mayo Clinic

Otolaryngology–Head and Neck Surgery | December 10, 2010 | Volume: 118 | Issue: 4 | Pages: 472-477

10.1177/019459989811800407 | PMID 9560097 Get It

It has been suggested that leukotrienes C4 (LTC4) and D4 (LTD4) released from upper respiratory mucosa influence mucociliary transport during allergic reactions. We studied the in vitro effects of leukotrienes C4 and D4 on the ciliary beat frequency (CBF) of human adenoid explants over a 5‐hour period. Tissue explants were cultured at 35° C in Minimum Essential Medium Eagle (MEM). The CBF was measured using phase contrast microscopy and microphotometry. Measurements of CBF were recorded in medium alone and in medium containing LTC4 or LTD4 at concentrations of 10−8 and 10−6 M. LTC4 and LTD4 increased CBF at concentrations of 10−8 and 10−6 M with increases of 20.51% ± 2.69% and 29.84% ± 4.06%, respectively. To determine the specificity of the LTC4 and LTD4 effects, the ciliated epithelium was treated with the specific leukotriene receptor antagonist LY‐171,883 before administration of LTC4 and LTD4. LY‐171,883 (10−6 M) significantly inhibited the ciliostimulatory effects of both leukotrienes. Our findings indicate that LTC4 and LTD4 increase CBF in vitro by activation of the LTD4 receptor.
Early experimental hypertension preserves the myocardial microvasculature but aggravates cardiac injury distal to chronic coronary artery obstruction
Caceres, Victor Hugo Urbieta, Lin, Jing , Zhu, Xiang-Yang, Gibson, Matthew E., Crane, John A., Lerman, Lilach O. , Favreau, Frederic D. , Lerman, Amir

Mayo Clinic

American Journal of Physiology-Heart and Circulatory Physiology | December 4, 2010 | Volume: 300 | Issue: 2 | Pages: H693-H701

10.1152/ajpheart.00516.2010 | PMID 21131477 Get It

Coronary artery disease is a leading cause of death. Hypertension (HT) increases the incidence of cardiac events, but its effect on cardiac adaptation to coexisting coronary artery stenosis (CAS) is unclear. We hypothesized that concurrent HT modulates microvascular function in chronic CAS and aggravates microvascular remodeling and myocardial injury. Four groups of pigs ( n = 6 each) were studied: normal, CAS, HT, and CAS+HT. CAS and HT were induced by placing local irritant coils in the left circumflex coronary artery and renal artery, respectively. Six weeks later multidetector computerized tomography (CT) was used to assess systolic and diastolic function, microvascular permeability, myocardial perfusion, and responses to adenosine in the “area at risk.” Microvascular architecture, inflammation, and fibrosis were then explored in cardiac tissue. Basal myocardial perfusion was similarly decreased in CAS and CAS+HT, but its response to adenosine was significantly more attenuated in CAS. Microvascular permeability in CAS+HT was greater than in CAS and was accompanied by amplified myocardial inflammation, fibrosis, and microvascular remodeling, as well as cardiac systolic and diastolic dysfunction. On the other hand, compared with normal, micro-CT-derived microvascular (20–200 μm) transmural density decreased in CAS but not in HT or CAS+HT. We conclude that the coexistence of early renovascular HT exacerbated myocardial fibrosis and vascular remodeling distal to CAS. These changes were not mediated by loss of myocardial microvessels, which were relatively preserved, but possibly by exacerbated myocardial inflammation and fibrosis. HT modulates cardiac adaptive responses to CAS and bears cardiac functional consequences.
Effect of Emphysema on Lung Cancer Risk in Smokers: A Computed Tomography–Based Assessment
Li, Yan , Swensen, Stephen J., Karabekmez, Leman Günbey , Marks, Randolph S., Stoddard, Shawn M., Jiang, Ruoxiang , Worra, Joel B., Zhang, Fang , Midthun, David E. , Song, Yong , Andrade, Mariza de , Yang, Ping

Mayo Clinic

Cancer Prevention Research | December 1, 2010 | Volume: 4 | Issue: 1 | Pages: 43-50

10.1158/1940-6207.capr-10-0151 | PMID 21119049 Get It

Abstract The contribution of emphysema to lung cancer risk has been recognized, but the effect size needs to be further defined. In this study, 565 primary lung cancer cases were enrolled though a prospective lung cancer cohort at Mayo Clinic, and 450 controls were smokers participating in a lung cancer screening study in the same institution using spiral computed tomography (CT). Cases and controls were frequency matched on age, gender, race, smoking status, and residential region. CT imaging using standard protocol at the time of lung cancer diagnosis (case) or during the study (control) was assessed for emphysema by visual scoring CT analysis as a percentage of lung tissue destroyed. The clinical definition of emphysema was the diagnosis recorded in the medical documentation. Using multiple logistic regression models, emphysema (≥5% on CT) was found to be associated with a 3.8-fold increased lung cancer risk in Caucasians, with higher risk in subgroups of younger (<65 years old, OR = 4.64), heavy smokers (≥40 pack-years, OR = 4.46), and small-cell lung cancer (OR = 5.62). When using >0% or ≥10% emphysema on CT, lung cancer risk was 2.79-fold or 3.33-fold higher than controls. Compared with CT evaluation (using criterion ≥5%), the sensitivity, specificity, positive and negative predictive values, and the accuracy of the clinical diagnosis for emphysema in controls were 19%, 98%, 73%, 84%, and 83%, respectively. These results imply that an accurate evaluation of emphysema could help reliably identify individuals at greater risk of lung cancer among smokers. Cancer Prev Res; 4(1); 43–50. ©2010 AACR.
Paracrine modulation of cholangiocyte serotonin synthesis orchestrates biliary remodeling in adults
Omenetti, Alessia , Yang, Liu , Gainetdinov, Raul R. , Guy, Cynthia D. , Choi, Steve S. , Chen, Wei , Caron, Marc G. , Diehl, Anna Mae

Mayo Clinic

American Journal of Physiology-Gastrointestinal and Liver Physiology | November 11, 2010 | Volume: 300 | Issue: 2 | Pages: G303-G315

10.1152/ajpgi.00368.2010 | PMID 21071507 Get It

Paracrine signaling between cholangiocytes and stromal cells regulates biliary remodeling. Cholangiocytes have neuroepithelial characteristics and serotonin receptor agonists inhibit their growth, but whether they are capable of serotonin biosynthesis is unknown. We hypothesized that cholangiocytes synthesize serotonin and that cross talk between liver myofibroblasts (MF) and cholangiocytes regulates this process to influence biliary remodeling. Transwell cultures of cholangiocytes ± MF, and tryptophan hydroxylase-2 knockin (TPH2KI) mice with an inactivating mutation of the neuronal tryptophan hydroxylase (TPH) isoform, TPH2, were evaluated. Results in the cell culture models confirm that cholangiocytes have serotonin receptors and demonstrate for the first time that these cells express TPH2 and produce serotonin, which autoinhibits their growth but stimulates MF production of TGF-β1. Increased TGF-β1, in turn, counteracts autocrine inhibition of cholangiocyte growth by repressing cholangiocyte TPH2 expression. Studies of TPH2KI mice confirm that TPH2-mediated production of serotonin plays an important role in remodeling damaged bile ducts because mice with decreased TPH2 function have reduced biliary serotonin levels and exhibit excessive cholangiocyte proliferation, accumulation of aberrant ductules and liver progenitors, and increased liver fibrosis after bile duct ligation. This new evidence that cholangiocytes express the so-called neuronal isoform of TPH, synthesize serotonin de novo, and deploy serotonin as an autocrine/paracrine signal to regulate regeneration of the biliary tree complements earlier work that revealed that passive release of serotonin from platelets stimulates hepatocyte proliferation. Given the prevalent use of serotonin-modulating drugs, these findings have potentially important implications for recovery from various types of liver damage.
Familial Aggregation of Left Ventricular Geometry and Association With Parental Heart Failure
Larson, Martin G. , Pencina, Michael J., Aragam, Jayashri, Redfield, Margaret M. , Benjamin, Emelia J. , Vasan, Ramachandran S. , Lam, Carolyn S.P. , Liu, Xuan , Yang, Qiong , Benjamin, Emelia J , Vasan, Ramachandran S

Mayo Clinic

Circulation: Cardiovascular Genetics | September 30, 2010 | Volume: 3 | Issue: 6 | Pages: 492-498

10.1161/circgenetics.110.941088 | PMID 20884845 Get It

Background— Data regarding the familial aggregation of left ventricular (LV) geometry and its relations to parental heart failure (HF) are limited. Methods and Results— We evaluated concordance of LV geometry within 1093 nuclear families in 5758 participants of the original (parents) (n=2351) and offspring (n=3407) cohorts of the Framingham Heart Study undergoing routine echocardiography in mid- to late adulthood. LV geometry was categorized based on cohort- and sex-specific 80th percentile cutoffs of LV mass and relative wall thickness (RWT) into normal (both <80th percentile), concentric remodeling (LV mass <80th percentile; RWT >80th percentile), concentric hypertrophy (both >80th percentile), and eccentric hypertrophy (LV mass >80th percentile; RWT <80th percentile). Within nuclear families, LV geometry was concordant among related pairs (parent-child, sibling-sibling) ( P =0.0015) but not among unrelated spousal pairs ( P =0.60), a finding that remained unchanged after adjusting for clinical covariates known to influence LV remodeling (age, systolic blood pressure, body mass index), excluding individuals with prevalent HF and myocardial infarction, and varying the thresholds for defining LV geometry. The prevalence of abnormal LV geometry was higher in family members of affected individuals, with recurrence risks of 1.4 for concentric remodeling (95% CI, 1.2 to 1.7) and eccentric hypertrophy (95% CI, 1.1 to 1.8) and 3.9 (95% CI, 3.2 to 4.6) for concentric hypertrophy. In a subset of 1497 offspring, we observed an association between parental HF (n=458) and eccentric hypertrophy in offspring ( P <0.0001). Conclusions— Our investigation of a 2-generational community-based sample demonstrates familial aggregation of LV geometry, with the greatest recurrence risk for concentric LV geometry, and establishes an association between eccentric LV geometry and parental HF.
TROY (TNFRSF19) Is Overexpressed in Advanced Glial Tumors and Promotes Glioblastoma Cell Invasion via Pyk2-Rac1 Signaling
Paulino, Vincent M., Kloss, Jean , Ennis, Matthew, Armstrong, Brock , Loftus, Joseph C. , Tran, Nhan L. , Yang, Zhongbo , Tran, Nhan L

Mayo Clinic

Molecular Cancer Research | September 30, 2010 | Volume: 8 | Issue: 11 | Pages: 1558-1567

10.1158/1541-7786.mcr-10-0334 | PMID 20881009 Get It

Abstract A critical problem in the treatment of malignant gliomas is the extensive infiltration of individual tumor cells into adjacent brain tissues. This invasive phenotype severely limits all current therapies, and to date, no treatment is available to control the spread of this disease. Members of the tumor necrosis factor (TNF) ligand superfamily and their cognate receptors regulate various cellular responses including proliferation, migration, differentiation, and apoptosis. Specifically, the TNFRSF19/TROY gene encodes a type I cell surface receptor that is expressed on migrating or proliferating progenitor cells of the hippocampus, thalamus, and cerebral cortex. Here, we show that levels of TROY mRNA expression directly correlate with increasing glial tumor grade. Among malignant gliomas, TROY expression correlates inversely with overall patient survival. In addition, we show that TROY overexpression in glioma cells activates Rac1 signaling in a Pyk2-dependent manner to drive glioma cell invasion and migration. Pyk2 coimmunoprecipitates with the TROY receptor, and depletion of Pyk2 expression by short hairpin RNA interference oligonucleotides inhibits TROY-induced Rac1 activation and subsequent cellular migration. These findings position aberrant expression and/or signaling by TROY as a contributor, and possibly as a driver, of the malignant dispersion of glioma cells. Mol Cancer Res; 8(11); 1558–67. ©2010 AACR.
Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903
Yao, Xiaopan, Cripe, Larry D., Li, Chin Yang, Litzow, Mark R. , Paietta, Elisabeth , Rowe, Jacob M. , Tefferi, Ayalew , Tallman, Martin S. , Mesa, Ruben A. , Li, Chin‐Yang

Mayo Clinic

Blood | July 22, 2010 | Volume: 116 | Issue: 22 | Pages: 4436-4438

10.1182/blood-2010-05-287417 | PMID 20651074 Get It

A multicenter Eastern Cooperative Group (ECOG) phase 2 trial assessed whether adding prednisone to lenalidomide would improve previously reported responses in persons with myelofibrosis (MF). Forty-eight subjects with anemia (42 evaluable) received lenalidomide, 10 mg/d, with a 3-month low-dose prednisone taper. Ten subjects received 3 months, and 25 received 6 months of therapy. Myelosuppression was the main toxicity with 88% with ≥ grade 3 hematologic toxicity and 45% ≥ grade 3 nonhematologic toxicity. There were responses in 10 subjects (23%) using the International Working Group for Myelofibrosis Research and Treatment (IWG-MRT)–defined clinical improvement of anemia in 8 (19%) and/or decreased spleen size in 4 (10%). Serial bone marrow analysis showed no resolution of disease-related fibrosis or angiogenesis. With a median follow-up of 2.3 years, 23 subjects are alive. Lenali-domide and prednisone for myelofibro-sis evaluated through a multicentered-cooperative group mechanism is only modestly active and myelosuppre-sive. This study was registered at http://clinicaltrials.gov as NCT00227591.
IC‐01‐01: Antemortem PiB binding correlates with postmortem amyloid density in a case with DLB on region of interest analysis
Yang, Chunhui , Reyes, Denise A., Lowe, Val J. , Aggarwal, Neelum T. , Petersen, Ronald C. , Kantarci, Kejal , Schneider, Julie A. , Senjem, Matthew L. , Barnes, Lisa L. , Bennett, David A. , Smith, Glenn E. , Knopman, David S. , Jack, Clifford R. , Boeve, Bradley F.

Mayo Clinic

Alzheimer's & Dementia | July 11, 2010 | Volume: 6 | Issue: 4S_Part_1 | Pages: No page available

10.1016/j.jalz.2010.05.007 Get It

Early atherosclerosis aggravates the effect of renal artery stenosis on the swine kidney
Urbieta-Caceres, Victor H., Lavi, Ronit, Zhu, Xiang-Yang, Crane, John A., Textor, Stephen C., Lerman, Lilach O. , Lerman, Amir

Mayo Clinic

American Journal of Physiology-Renal Physiology | May 13, 2010 | Volume: 299 | Issue: 1 | Pages: F135-F140

10.1152/ajprenal.00159.2010 | PMID 20462971 Get It

Atherosclerotic renal artery stenosis (ARAS) is increasingly identified in patients with end-stage renal disease. Renal function in ARAS patients deteriorates more frequently than in nonatherosclerotic renal artery stenosis (RAS). This study was designed to test the hypothesis that atherosclerosis modifies the relationship between single-kidney hemodynamics and function and the severity of stenosis. The degree of unilateral RAS in domestic pigs (4 normal, 26 RAS, and 22 ARAS) was correlated with renal function and hemodynamics evaluated by 64-slice multidetector computerized tomography before and after endothelium-dependent challenge with ACh. The degree of stenosis and increase in mean arterial pressure were similar in RAS and ARAS. Stenotic single-kidney volume, blood flow, glomerular filtration rate, and cortical perfusion were lower than normal in both RAS and ARAS, but only in RAS correlated inversely with increasing degree of stenosis ( r = −0.62, r = −0.49, r = −0.51, and r = −0.46, respectively, P < 0.05 for all). Basal tubular fluid concentration capacity and stenotic cortical perfusion response to ACh were both blunted only in ARAS. This study shows that atherosclerosis modulates the impact of a stenosis in the renal artery on stenotic kidney hemodynamics, function, and tubular dynamics. These observations underscore the direct intrarenal effect of atherogenic factors on the kidneys.
A Second Genetic Variant on Chromosome 15q24-25.1 Associates with Lung Cancer
Liu, Pengyuan , Wu, Xifeng , Vikis, Haris G., Wang, Yian , Schwartz, Ann G. , Pinney, Susan M. , Gazdar, Adi F., Gaba, Colette , Mandal, Diptasri , Lee, Juwon , Kupert, Elena, Seminara, Daniela, Bailey‐Wilson, Joan E. , Spitz, Margaret R., Anderson, Marshall W., You, Ming , Yang, Ping , Lü, Yan , Andrade, Mariza de , Gazdar, Adi, Minna, John Dorrance , Amos, Christopher I. , Wilson, Richard K , Pinney, Susan M

Mayo Clinic

Cancer Research | April 15, 2010 | Volume: 70 | Issue: 8 | Pages: 3128-3135

10.1158/0008-5472.can-09-3583 | PMID 20395203 Get It

Abstract A common variant on chromosomal region 15q24-25.1, marked by rs1051730, was found to be associated with lung cancer risk. Here, we attempted to confirm the second variant on 15q24-25.1 in several large sporadic lung cancer populations and determined what percentage of additional risk for lung cancer is due to the genetic effect of the second variant. SNPs rs1051730 and rs481134 were genotyped in 2,818 lung cancer cases and 2,766 controls from four populations. Joint analysis of these two variants (rs1051730 and rs481134) on 15q24-25.1 identified three major haplotypes (G_T, A_C, and G_C) and provided stronger evidence for association of 15q24-25.1 with lung cancer (P = 9.72 × 10−9). These two variants represent three levels of risk associated with lung cancer. The most common haplotype G_T is neutral; the haplotype A_C is associated with increased risk for lung cancer with 5.0% higher frequency in cases than in controls [P = 1.68 × 10−7; odds ratio (OR), 1.24; 95% confidence interval (95% CI), 1.14–1.35]; whereas the haplotype G_C is associated with reduced risk for lung cancer with 4.4% lower frequency in cases than in controls (P = 7.39 × 10−7; OR, 0.80; 95% CI, 0.73–0.87). We further showed that these two genetic variants on 15q24-25.1 independently influence lung cancer risk (rs1051730: P = 4.42 × 10−11; OR, 1.60; 95% CI, 1.46–1.74; rs481134: P = 7.01 × 10−4; OR, 0.81; 95% CI, 0.72–0.92). The second variant on 15q24-25.1, marked by rs481134, explains an additional 13.2% of population attributable risk for lung cancer. Cancer Res; 70(8); 3128–35. ©2010 AACR.